ORIGINAL RESEARCH
Published on 22 May 2025
Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study
doi 10.3389/fimmu.2025.1579483
- 427 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Innovative Immunotherapy Strategies for Enhanced Treatment of Hodgkin and Non-Hodgkin Lymphomas
Innovative Immunotherapy Strategies for Enhanced Treatment of Hodgkin and Non-Hodgkin Lymphomas
6,689
Total downloads
27k
Total views and downloads
Articles
CASE REPORT
Published on 08 May 2025
Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma
doi 10.3389/fimmu.2025.1567149
- 768 views
REVIEW
Published on 26 Feb 2025
Advances in primary large B-cell lymphoma of immune-privileged sites
doi 10.3389/fimmu.2025.1533444
- 1,896 views
CASE REPORT
Published on 09 Dec 2024
Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma
doi 10.3389/fimmu.2024.1497736
- 1,506 views
- 1 citation
ORIGINAL RESEARCH
Published on 06 Dec 2024
Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression
doi 10.3389/fimmu.2024.1483617
- 970 views
ORIGINAL RESEARCH
Published on 02 Dec 2024
Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell lymphoma
doi 10.3389/fimmu.2024.1481080
- 1,262 views
ORIGINAL RESEARCH
Published on 25 Sep 2024
Metabolite, immunocyte phenotype, and lymphoma: a Mendelian randomization study
doi 10.3389/fimmu.2024.1431261
- 2,613 views
ORIGINAL RESEARCH
Published on 23 Sep 2024
Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma
doi 10.3389/fimmu.2024.1466859
- 1,170 views
CORRECTION
Published on 09 Sep 2024
Corrigendum: Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia
doi 10.3389/fimmu.2024.1483043
- 651 views
- 1 citation
ORIGINAL RESEARCH
Published on 13 Aug 2024
Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia
doi 10.3389/fimmu.2024.1415328
- 2,096 views
- 1 citation
ORIGINAL RESEARCH
Published on 25 Jun 2024
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL
doi 10.3389/fimmu.2024.1410638
- 1,766 views
- 1 citation
ORIGINAL RESEARCH
Published on 14 May 2024
Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy
doi 10.3389/fimmu.2024.1393485
- 6,020 views
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore